GSK and Sanofi to develop an adjuvanted vaccine for COVID-19

Sanofi will use its S-protein COVID-19 antigen to develop the vaccine candidate. GSK will boost the antigen with its pandemic adjuvant technology. Trials are planned for the second half of this year and, if successful could be available for use in the second half of 2021

Biospace Inc.